Who is sponsoring NCT03928041?

NCT03928041 is sponsored by Invibio Ltd.

What drugs are being tested in NCT03928041?

Interventions in NCT03928041: Device: EVOS Lumbar Interbody System (EVOS-HA).

What condition does NCT03928041 study?

NCT03928041 studies Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1.

Is NCT03928041 still recruiting?

NCT03928041 is currently completed. Last updated 30 April 2025.

Last reviewed 2025-04-30 · How we verify

NCT03928041

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced Interbody Cages in the Lumbar Spine

Completed NA Last updated 30 April 2025

What this trial tests

NA trial testing Device: EVOS Lumbar Interbody System (EVOS-HA) in Degenerative Disc Disease Lumbar in 22 participants. Completed in 25 September 2023.

Timeline

27 June 2019

Primary endpoint
22 May 2023

25 September 2023

Quick facts

Lead sponsor	Invibio Ltd
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	27 June 2019
Primary completion	22 May 2023
Estimated completion	25 September 2023
Sites	2 locations across United States

Drugs / interventions tested

Device: EVOS Lumbar Interbody System (EVOS-HA)

Conditions studied

Degenerative Disc Disease Lumbar — all drugs for Degenerative Disc Disease Lumbar →
Spondylolisthesis, Grade 1 — all drugs for Spondylolisthesis, Grade 1 →

Sponsor

Invibio Ltd

Who can join

18 and older, any sex, with Degenerative Disc Disease Lumbar or Spondylolisthesis, Grade 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is to collect clinical outcomes including radiographic and CT outcomes in patients who undergo interbody spinal fusion using the EVOS Lumbar Interbody System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Invibio Ltd trials

Trials by the same sponsor.

NCT06585267 — Development of a New Patient Reported Outcome Measure (PROM) to Assess Patient's Emotional Wellbeing, and Perceptions of · active not recruiting
NCT05692687 — A Post-market Clinical Study to Evaluate the Safety and Performance of the Carbon Fibre Reinforced Polyetheretherketone · completed
NCT05597046 — Qualitative Interviews With Healthcare Professionals · completed
NCT04416321 — A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03928041 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Invibio Ltd
Last refreshed: 30 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03928041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing